Literature DB >> 3013714

Nifedipine: more than a calcium channel blocker.

T H Swanson, C L Green.   

Abstract

Nifedipine exhibits a greater incidence of side effects than the other currently marketed calcium channel antagonists. In addition to those effects attributable to calcium channel blockade, nifedipine produces side effects similar to the effects of adenosine. It is probable that nifedipine exerts part of its physiological actions through potentiation of adenosine. Adenosine, an endogenous calcium channel blocker, modifies synaptic events throughout the nervous system and causes sedation, smooth and skeletal muscle relaxation, anticonvulsion, hypotension and hypothermia, all reversible by caffeine or theophylline administration. Nifedipine inhibits adenosine uptake from, and release into, the extracellular space and binds at an adenosine receptor. Both nifedipine and adenosine interact with benzodiazepine binding sites. Interaction between nifedipine and adenosine should be kept in mind when treating patients with nifedipine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013714     DOI: 10.1016/0306-3623(86)90038-8

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  4 in total

1.  Interaction of dihydropyridine calcium channel agonists and antagonists with adenosine receptors.

Authors:  P S Hu; E Lindgren; K A Jacobson; B B Fredholm
Journal:  Pharmacol Toxicol       Date:  1987-08

2.  The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration.

Authors:  J van Harten; J Burggraaf; M Danhof; P van Brummelen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

3.  Dihydropyridines alter adenosine sensitivity in the rat hippocampal slice.

Authors:  J T Bartrup; T W Stone
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

4.  In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen.

Authors:  N Kretschy; M Teichmann; S Kopf; A G Atanasov; P Saiko; C Vonach; K Viola; B Giessrigl; N Huttary; I Raab; S Krieger; W Jäger; T Szekeres; S M Nijman; W Mikulits; V M Dirsch; H Dolznig; M Grusch; G Krupitza
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.